Investment Committee Summary
| Rating | HOLD |
| Internal 5-tier | HOLD |
| Classification · conviction | mature cash generator · medium |
| Evidence | 8/8 load-bearing inputs sourced |
| Triangulated fair value | $56.59 (-11% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $61.71 (-3% vs spot · 12m PWEV) |
| Next catalyst | 2026-10-26 — Quarterly earnings |
| Primary thesis-break | Total revenue growth, year-on-year (as reported) < 0.035 (2 consecutive prints) |
Decision detail — rating tables & Research OS strip
Rating: HOLD
Internal 5-tier: HOLD · mature cash generator · analyst conviction: medium
| Metric | Value |
|---|---|
| Current Price | $63.65 |
| Triangulated Fair Value | $56.59 (-11% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $61.71 (-3% vs spot · 12m PWEV) |
| Forward P/E | 14.2x |
| Market Cap | $21B |
| 52-Week Range | $53.81–$95.69 (intraday high and low over the trailing 52 weeks of the stock's own daily bars) |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across four weighted anchors — an intrinsic DCF, a scenario-weighted PWEV, a Monte Carlo median (Student-t + regime switching) and a peer P/E re-rate. Anchors are blended at fixed declared weights, each counted separately; the Monte Carlo, the scenario PWEV and the DCF's exit-multiple terminal all rest on the same base multiple, so where they agree it is partly by construction — not independent corroboration. Figures reconciled to Alpha Vantage 2026-10-12. Each chart below sits with the part of the thesis it evidences.
General research, published identically to every reader. Not personal financial advice. Figures as of the analysis date; verify before acting.
Decision Support — Research OS jump to detail ↓
| Research conviction | Exp. return (1y) | Rules stance | Next catalyst |
|---|---|---|---|
| 55.0/100 (39th pct) | -2% 1yr expected | Hold | 13d — Quarterly earnings |
Full breakdown — conviction components, probability-return distribution, decision rules, factor & portfolio interaction and the catalyst timeline — in the Decision Support sections below. Model output for research; not personal financial advice.
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Recommendation: HOLD
Balanced: triangulated fair value $56.59 (-11% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.
Investment Thesis
At $63.65 (13 October 2026) Brown & Brown trades on 14x forward earnings against a higher insurance-broker peer median, and well below its 52-week high. The market is pricing a roll-up that levered up near the top of the commercial property and casualty pricing cycle, just as that cycle softens. The engine partly agrees. Probability-weighting the tree gives $61.71, and the triangulated fair value lands at $56.59, or -11% against the current price, leaving the shares fairly valued against that estimate; the capex-bridge discounted cash flow and the simulated median read lower again, and most of the simulated variance is carried by the multiple rather than by the business drivers. The Gordon terminal and the peer cross-read argue the discount is overdone, but they do not carry the blend. HOLD follows.
Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.
The dashboard below is the whole argument on one page: spot ($63.65) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The steelman bear is mechanical, not sentimental. Commercial property and casualty pricing has compounded for years; when the cycle turns, broker commissions fall with premium rates while expense bases built for a hard market do not. The structural scenario's target, below the 52-week low, is the honest price of that combination — and it is the heaviest weight on the downside of the tree, not a stress-test flourish.
Key Debate
P/E Multiple explains 72% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
What the Market Is Pricing In
At the current price, the market pays 14.2× consensus forward EPS, vs the house DCF terminal 12.0×, and a peer median 16.1×. The house DCF sits 24% below spot, so the market is pricing in more than the house case — roughly 1.9pp of revenue CAGR.
Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 7.0 | 6.7 | High |
| EPS | 4.5 | 4.5 | Medium |
| Target price | 75.1 | 61.8 | Medium |
Scenario Analysis
The scenario tree spans a structural 'Structural — Soft-Market / Commission Pressure' downside ($32.30) to a 'Bull — Defensive Re-Rate' bull case ($98.40); the probability-weighted blend (PWEV $61.71) is -3% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Soft-Market / Commission Pressure | 20% | $32.30 | -49% |
| Economic / Exposure Recession | 17% | $52.00 | -18% |
| Base — Organic + Pricing + M&A | 35% | $64.70 | +2% |
| Growth — Specialty / International / Consolidation | 20% | $84.10 | +32% |
| Bull — Defensive Re-Rate | 8% | $98.40 | +55% |
| Probability-Weighted (PWEV, after SBC dilution) | — | $61.71 | -3% |
SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (1.5% of shares, on SBC ≈ 2% of revenue), trimming the gross PWEV of $62.64 to $61.71 (-1.5%). SBC is charged once, as dilution — never also deducted from FCF.
Scenario rationale — the driver path behind every target:
- Structural — Soft-Market / Commission Pressure (20%, $32.30). Structural impairment — soft-market / commission pressure: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
- Economic / Exposure Recession (17%, $52.00). Cyclical downturn — brokerage organic growth + P&C pricing cycle + bolt-on M&A (fee/commission, no underwriting risk) weakens for 1–2 years before normalising.
- Base — Organic + Pricing + M&A (35%, $64.70). Mid-cycle — normalised brokerage organic growth + P&C pricing cycle + bolt-on M&A (fee/commission, no underwriting risk); disciplined capital allocation; steady returns.
- Growth — Specialty / International / Consolidation (20%, $84.10). Upside — specialty / international / consolidation lifts earnings above mid-cycle; the multiple expands modestly.
- Bull — Defensive Re-Rate (8%, $98.40). Upside tail — sustained tight conditions or a structural re-rate on specialty / international / consolidation.
Valuation Triangulation
Four weighted anchors — an intrinsic dcf, a scenario-weighted pwev, a monte carlo median (student-t + regime switching) and a peer p/e re-rate — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat four numbers as four independent votes.
| Method | Basis | Fair Value | vs Spot | Weight in this name's blend |
|---|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $56.67 | -11% | 18% (declared 15%) |
| Peer P/E re-rate | multiple | $72.10 | +13% | 12% (declared 10%) |
| Peer EV/Revenue re-rate | multiple | $57.97 | -9% | 0% — cross-check only |
| Scenario PWEV | multiple | $61.71 | -3% | 29% (declared 25%) |
| DCF (5-year + exit-multiple terminal) | cash flow + terminal × | $48.46 | -24% | 41% (declared 35%) |
| Triangulated (weighted) | — | $56.59 | -11% | 100% |
The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts is not computed, so 15% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.
Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.
Monte Carlo — the outcome distribution
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $56.67 and 36% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (72% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — explicit-period cash flows with an exit-multiple terminal
A 5-year cash-flow path discounted at a WACC of 8.0%, plus a terminal value of final-year FCF × 12.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $48.46. The terminal value is 70% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (41%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.
Peer benchmarking — relative value
Against its 4 peers in the same GICS sub-industry, re-rating to their median forward multiple (P/E 16.1x) implies $72.10. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so market sentiment does not set the fair value.
Across all anchors the spread is 41% of the median — wide (genuine disagreement — the blend carries low valuation confidence).
Sensitivity
DCF/share — WACC × terminal multiple
| WACC \ Term× | 8.4x | 10.2x | 12.0x | 13.8x | 15.6x |
|---|---|---|---|---|---|
| 6.0% | $38.31 | $46.40 | $54.49 | $62.58 | $70.66 |
| 7.0% | $35.96 | $43.67 | $51.39 | $59.11 | $66.83 |
| 8.0% | $33.72 | $41.09 | $48.46 | $55.82 | $63.19 |
| 9.0% | $31.60 | $38.64 | $45.67 | $52.71 | $59.74 |
| 10.0% | $29.59 | $36.31 | $43.03 | $49.75 | $56.47 |
DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)
| CAGRΔ \ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $33.95 | $37.03 | $40.10 | $43.18 | $46.26 |
| -1.5pp | $37.62 | $40.89 | $44.17 | $47.44 | $50.72 |
| +0.0pp | $41.48 | $44.97 | $48.46 | $51.94 | $55.43 |
| +1.5pp | $45.56 | $49.27 | $52.98 | $56.68 | $60.39 |
| +3.0pp | $49.86 | $53.80 | $57.74 | $61.68 | $65.62 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Revenue CAGR ±3pp | $40.00 | $58.00 | $18.00 |
| Terminal × ±15% | $41.00 | $56.00 | $15.00 |
| Model op margin ±3pp | $41.00 | $55.00 | $14.00 |
| WACC ±1pp | $46.00 | $51.00 | $6.00 |
| Capex intensity ±15% | $48.00 | $49.00 | $1.00 |
Company lever — value at the base multiple vs Insurance Brokerage multiple (base 13.0x)
| Multiple | 9.1x | 11.0x | 13.0x | 14.9x | 16.9x |
|---|---|---|---|---|---|
| Value at the base multiple (EBIT × multiple; illustrative, not a blend anchor) | $32.00 | $43.00 | $55.00 | $66.00 | $78.00 |
Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.
Peer Quality & Weighting
| Peer | Fwd P/E | Growth | Op margin | Quality | Weight cap |
|---|---|---|---|---|---|
| MRSH | 15.7× | 7% | 24% | direct | 100% |
| AON | 17.1× | 7% | 36% | direct | 100% |
| AJG | 16.5× | 7% | 28% | direct | 100% |
| WTW | 13.8× | 7% | 20% | direct | 100% |
Quality-weighted forward P/E: 15.8× (simple median 16.1×). Direct peers count 100%, segment 50%, broad 25%.
Historical-range cross-check: 52-week range $53.81–$95.69, centre $71.80 (+13% vs spot); spot sits at the 23rd percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV (FV ÷ price − 1) | $56.59 (-11% vs spot · triangulated FV) |
| Downside to lowest scenario (Structural — Soft-Market / Commission Pressure) | $32.30 (-49% vs spot · bear scenario) |
| Reward-to-risk ratio | withheld — the triangulated FV is at or below spot, so there is no reward leg to divide by the risk leg |
| Discount to fair value (1 − price ÷ FV) | -12% |
| P(price > spot) — Monte Carlo | 36% |
That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Soft-Market / Commission Pressure' target ÷ price). 'Structural — Soft-Market / Commission Pressure' ($32.30, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Defensive Re-Rate): $98.40.
Company Overview & Business Model
Brown & Brown Inc — FINANCIAL SERVICES · INSURANCE BROKERS. Brown & Brown, Inc. markets and sells insurance products and services in the United States, Bermuda, Canada, the Cayman Islands, Ireland, and the United Kingdom. The company is headquartered in Daytona Beach, Florida.
Company description as supplied by Alpha Vantage; not checked against the company's filings.
How it makes money.
| Segment | Rev mix | Growth | Model op margin† | Key driver |
|---|---|---|---|---|
| Insurance Brokerage | 100% | +7% | 30% | brokerage organic growth + P&C pricing cycle + bolt-on M&A (fee/commission, no underwriting risk) |
† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.
Edge. Narrow moat — Insurance broking is capital-light, sticky and high-retention (fee/commission, no underwriting risk) - but the moat is narrow: it rests on local relationships and acquisition sourcing, not a structural barrier, and larger brokers (AON, MMC, WTW) compete for the same accounts. The premium is really an M&A-compounding multiple. Falsifiable: if organic growth normalizes to low-single-digits as the P&C pricing cycle softens and bolt-on multiples rise, the ~13x it trades at is not justified above it and should not re-rate toward the 16x broker peer median.
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Model op margin† | Model EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Insurance Brokerage | $6.3B | 100% | 7% | 30% | $1.9B | 13.0x | 2% | ESTIMATE |
| † Model EBIT = revenue × the model margin, i.e. gross margin less the opex ratio the calibration solved for to meet the EPS target — not the company's reported operating income. |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | brokerage organic growth + P&C pricing cycle + bolt-on M&A (fee/commission, no underwriting risk) |
| net_debt_or_cash_b | -7.06 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.02 |
| div_yield | 0.0102 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | soft-market / commission pressure |
| upside | specialty / international / consolidation |
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $6.8B — levered |
| Net debt / EBITDA | 2.36x |
| Interest coverage (EBIT / interest) | 5.6x |
| Current ratio | 1.04x |
| Lease obligations | $0.3B |
| Cash & ST investments | $1.1B |
Balance-sheet data as of 2025-12-31 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $1.4B |
| Buybacks / dividends | $0.1B / $0.2B |
| Total shareholder yield | 1.4% |
| Payout as % of FCF | 21.3% |
| Reinvestment (capex / OCF) | 4.7% |
| SBC as % of FCF | 6.7% |
| Allocation stance | reinvesting |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | 21.9% |
| FCF conversion (FCF / net income) | 129.5% |
| FCF yield | 6.7% |
| Capex intensity (capex / revenue) | 1.1% |
| FCF − SBC (diagnostic) | $1.3B |
| Capex split (maint / growth) | 75% / 25% — Capital-light broker (~2% capex/rev); PP&E is minimal. The dominant growth spend is acquisition, funded off balance sheet and not in this line. On-P&L capex is largely maintenance IT/office; growth share reflects platform/technology and producer tooling. |
Accounting quality: SBC 2% of revenue; cash conversion (OCF/NI) 136% — cash-backed.
Competitive Moat
Moat sources:
- High client-retention and renewal economics (~90%+) in commercial P&C mid-market
- Decentralized, incentive-aligned producer culture and local relationships
- Disciplined bolt-on M&A machine - a process moat, not a structural one
- No underwriting/balance-sheet risk - capital-light recurring-commission model
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q2): management +0.18 vs analyst floor -0.00 → delta +0.19 (n=39 mgmt / 28 Q&A; 7th pctile across the S&P book, z -1.5).
Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q2 | +0.18 | -0.00 | +0.19 |
| 2026Q1 | +0.25 | +0.00 | +0.25 |
| 2025Q4 | +0.24 | +0.10 | +0.14 |
| 2025Q3 | +0.38 | +0.24 | +0.14 |
News (last 365d, 1383 articles): avg ticker sentiment +0.13 (bullish 19% / bearish 6%)
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $75.06 (+18% vs spot · street) |
| House target | $61.82 (-17.6% vs street) |
| Sell-side coverage | 19 analysts (SB 2 / B 2 / H 14 / S 1 / SS 0; net score 0.13) |
| Consensus FY EPS | $4.48 (reference only — house values on EV/EBITDA) |
| Consensus FY revenue | $7.0B; house below (-4.1%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Catalyst Calendar
- 2026-10-26 (~14d) — Quarterly earnings — est. EPS $1.09 (AV EARNINGS_CALENDAR)
- 2026-10-27 (~15d) — Investor day / long-term organic-growth and margin framework (authored)
- 2027-01-15 (~95d) — January 1 P&C commercial renewal pricing read (authored)
Forecast Track Record
- EPS surprise: beat 75% of the last 8 quarters; average surprise +4.5%.
Catalyst Timeline
6 catalysts in the next 90 days (of 14 tracked). Importance 1–3; confidence 0–1.
| When | Catalyst | Type | Importance | Confidence |
|---|---|---|---|---|
| 2026-10-14 (in 1d) | September CPI | macro | ●● | 0.8 |
| 2026-10-26 (in 13d) | Quarterly earnings | earnings | ●●● | 0.95 |
| 2026-10-27 (in 14d) | Investor day / long-term organic-growth and margin framework | authored | ● | 0.7 |
| 2026-10-28 (in 15d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2026-12-09 (in 57d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2026-12-18 (in 66d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-01-15 (in 94d) | January 1 P&C commercial renewal pricing read | authored | ● | 0.7 |
| 2027-01-27 (in 106d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-03-17 (in 155d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-03-19 (in 157d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-04-28 (in 197d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-06-09 (in 239d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-06-18 (in 248d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-09-17 (in 339d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
_Sources: extended.catalysts, data/catalysts/
Regulatory & Legal Risk
| Issue | Probability | Valuation sensitivity | Horizon |
|---|---|---|---|
| Broker-compensation / contingent-commission disclosure scrutiny | low (~20%) | low - modest fee-transparency risk; ~2-3% of FV | 12-24m |
| Interest-rate path affecting fiduciary-investment income and deal-financing cost on net debt | medium (~40%) | medium - float income + leverage cost; ~4-5% of FV | 12-24m |
Probabilities and sensitivities are analyst estimates, not market-implied.
Scenario Macro & Key Risks
| Scenario | Macro assumption | Key risk |
|---|---|---|
| Economic / Exposure Recession | Recession shrinks insurable exposure units (payroll, revenue, property values), cutting the commission base. | Exposure contraction compounds soft pricing, pushing organic growth negative. |
| Base — Organic + Pricing + M&A | Moderate P&C pricing, mid-single-digit organic growth and a steady bolt-on cadence at disciplined multiples. | Leverage near cycle top constrains M&A firepower if credit tightens. |
| Growth — Specialty / International / Consolidation | Firm P&C pricing plus specialty/international expansion and continued industry consolidation. | Rising acquisition multiples erode the returns on the M&A engine. |
| Bull — Defensive Re-Rate | Market rewards the recurring, recession-resilient fee model with a defensive re-rate. | Re-rate unwinds if the pricing cycle turns and organic growth disappoints. |
Scenario-macro rows withheld pending re-authoring: 1 carrying another cluster's vocabulary or a frozen figure — recorded in the narrative quarantine ledger.
Decision Rules (Machine-Checked)
Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).
| Rule | Condition | Observed | Triggered |
|---|---|---|---|
| R1-valuation-stretch | expected return vs fair value < -12 (upside_pct) |
-2.87 | no |
| R2-valuation-opportunity | expected return vs fair value > 15 (upside_pct) |
-2.87 | no |
| R3-street-revisions | street net rating stance < -0.25 (extended.consensus.street_score) |
0.13 | no |
| R4-earnings-quality | cash conversion of earnings < 80 (extended.accounting_quality.cash_conversion_pct) |
135.9 | no |
| R5-technical-breakdown | price vs 200-day SMA < 0.85 (technicals.sma_200) |
0.95 | no |
| R6-vol-regime-shift | IV/RV vol-risk premium > 1.4 (options_overlay.iv_rv) |
1.12 | no |
Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- Total revenue growth, year-on-year (as reported) < 0.035 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- Operating margin, quarterly annualised < 0.286 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- US commercial P&C composite renewal rate change (CIAB quarterly survey) < 0.0 (2 consecutive prints). Commission revenue is geared to premium rates. Two consecutive quarters of negative composite renewal pricing marks a broad soft market rather than line-specific softening, and precedes the revenue effect by two to three quarters.
- Net debt / EBITDA > 3.5 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
- Diluted EPS, trailing four quarters annualised < 4.57 (2 consecutive prints). (rationale withheld pending re-authoring — frozen figure or verdict)
Fact / Inference / Speculation
- FACT: Spot $63.65; 52-week range $53.81–$95.69; engine rating HOLD; house target $61.82 (-3%). (source: Alpha Vantage 2026-10-12, 13 October 2026)
- INFERENCE: Triangulated FV $56.59 (-11% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.
Conviction Score
Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.
55.0/100 (confidence band 43.2–66.7), 39th percentile of 928 covered names (as of 2026-10-12). Weighted composite under config ros-1.21.0 — every component and its inputs below.
| Component | Score (0–100) | Weight | Inputs |
|---|---|---|---|
| business quality | 72 | 15% | extended.fcf_quality.fcf_margin_pct, extended.balance_sheet.net_debt_to_ebitda, extended.accounting_quality.cash_conversion_pct |
| financial strength | 40 | 10% | extended.balance_sheet.net_debt_to_ebitda, extended.balance_sheet.interest_coverage |
| valuation | 47 | 15% | upside_pct |
| growth | 56 | 10% | reconciliation.ttm_revenue_billions, reconciliation.fy_guide_revenue_billions |
| earnings visibility | 75 | 10% | extended.forecast_accuracy.eps_surprise.beat_rate_pct |
| moat | 57 | 10% | enrichment.moat.rating |
| technical trend (heuristic — no validation record; weight change reserved for AM-060) | 28 | 10% | technicals.rsi, technicals.sma_50, technicals.sma_200 |
| macro tailwinds | — | 10% | industry_context.scenario_states |
| risk profile | 60 | 10% | monte_carlo.prob_above_current, monte_carlo.p10, monte_carlo.p90, monte_carlo.median |
Missing inputs (macro tailwinds) are excluded and the remaining weights renormalised; the confidence band widens accordingly.
Score history: 55.1 → 54.9 → 55.1 → 55.1 → 55.3 → 54.9 → 55.3 → 55.3.
Probability-Weighted Return Profile
Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.
| Scenario | Probability | Target | Total return | Contribution |
|---|---|---|---|---|
| Structural — Soft-Market / Commission Pressure | 20% | $32.30 | -49.3% | -9.8pp |
| Economic / Exposure Recession | 17% | $52.00 | -18.3% | -3.1pp |
| Base — Organic + Pricing + M&A | 35% | $64.70 | +1.6% | +0.6pp |
| Growth — Specialty / International / Consolidation | 20% | $84.10 | +32.1% | +6.4pp |
| Bull — Defensive Re-Rate | 8% | $98.40 | +54.6% | +4.4pp |
| Aggregate | Value |
|---|---|
| Expected return (gross, 1y) | -1.6% |
| Expected return net of SBC dilution | -3.0% |
| Outcome dispersion (σ, from MC p10–p90) | 30.5% |
| Expected Sharpe (rf 4%) | -0.18 |
| Downside expectation (prob-weighted loss branches) | -13.0% |
The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.
Expected Alpha
Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).
| Component | Value |
|---|---|
| Expected return (gross, 1y) | -1.6% |
| Risk-free rate | 4.49% (1y proxy (3m/2y midpoint; AV lacks a 1y tenor), as of 2026-10-08) |
| Beta (shrunk, 1y vs SPY) | 0.13 (as of 2026-10-12) |
| Equity risk premium | 4.5% |
| Required return | 5.1% |
| Expected alpha | -6.7% |
| Alpha per unit risk (EA/σ) | -0.22 |
A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.
Probability Cross-Checks
Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.
| Cross-check | Ours | Comparator | Reading |
|---|---|---|---|
| Scenario spread vs options market | 31.4% (1σ) | 26.0% implied | broadly consistent with the market's implied uncertainty |
| Mass above spot: scenarios vs our own MC | 63.0% | 36.4% | the scenario weights and the MC parameters disagree about our OWN view — this is a model-coherence issue, not a market disagreement |
| Realised scenario frequency | 59 dated anchors | — | 59 dated anchors available; realised-vs-prior comparison is now meaningful. |
Authored set: 5 scenarios, probabilities summing to 1.0, mean target $62.64.
Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.
Factor Exposures
Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.
| Style | Percentile | Theme | Percentile | |
|---|---|---|---|---|
| Growth | 57 | AI | 0 | |
| Value | 31 | Cloud | 63 | |
| Quality | 37 | Semis | 0 | |
| Momentum | 10 | Consumer | 18 | |
| Low-Vol | 24 | Rates | 15 | |
| USD | 98 | |||
| Energy | 81 |
Market interaction: correlation vs SPY +0.15, vs QQQ -0.00 (trailing ~1y daily returns).
Rating Bridge
Rating = HOLD because:
- Probability-weighted scenario value implies -3% vs spot
- Monte Carlo median implies -11% vs spot
- DCF fair value (exit-multiple terminal) implies -24% vs spot — but this is terminal-value sensitive (exit-multiple $48.46 vs Gordon $75.61, 56% apart), so it carries less weight
- Bear case (Structural — Soft-Market / Commission Pressure) downside is -49% vs spot
- Net: the valuation anchor itself sits 11.1% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.
Model Appendix
DCF — line items
| Year | Revenue | Op income (house path) | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $7B | $2B | $0B | $0B | $1B | $1B |
| FY+2 | $7B | $2B | $0B | $0B | $2B | $1B |
| FY+3 | $8B | $2B | $0B | $0B | $2B | $1B |
| FY+4 | $8B | $2B | $0B | $0B | $2B | $1B |
| FY+5 | $8B | $3B | $0B | $0B | $2B | $1B |
| Terminal | — | — | — | — | $2B × 12.0x | $16B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 2% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.0% · Σ PV(FCF) $7B + PV(terminal) $16B = EV $23B; − net debt $7.1B → equity $16B ÷ diluted shares $0.32B = $48.46/share (exit-multiple terminal).
- Gordon terminal → $75.61/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
- Incremental ROIC on the forecast capex ≈ 107% vs WACC 8.0% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| MRSH | 3.6x | 15.7x | 7% | 24% |
| AON | 4.8x | 17.1x | 7% | 36% |
| AJG | 4.6x | 16.5x | 7% | 28% |
| WTW | 3.0x | 13.8x | 7% | 20% |
| Median | 4.1x | 16.1x | — | — |
Implied prices at the peer medians: same-sub-industry median fwd P/E → $72.10; EV/Rev → $57.97.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $48.46 | 41% | $19.95 |
| Scenario PWEV | $61.71 | 29% | $18.15 |
| Monte Carlo median | $56.67 | 18% | $10.00 |
| Peer P/E | $72.10 | 12% | $8.48 |
| Triangulated | — | 100% | $56.59 |
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 8.0% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 12× | DCF exit value | house rule (0.85 × base multiple) |
| Terminal growth | 2.5% | Gordon cross-check (single point) | estimate |
| SBC dilution | 1.5%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Revenue CAGR ±3pp (18.0); Terminal × ±15% (15.0); Model op margin ±3pp (14.0); WACC ±1pp (6.0); Capex intensity ±15% (1.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $6.3B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $6.7B | company guidance | Company guidance | Medium | Forecast, SoP |
| FY+1 guided EPS | $4.4823 | company guidance | Company guidance | Medium | Forward P/E, scenarios |
| Consensus FY EPS | $4.4823 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.323B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $6.839B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 8.0% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 12× | house estimate | House rule: 0.85 × the base multiple (shared with the Monte Carlo) | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | Gordon cross-check (single point, not in the blend) |
| SBC dilution | 1.5%/yr | house estimate | From SBC/revenue | Medium | PWEV, MC, DCF (charged once) |
Research Provenance
| Field | Value |
|---|---|
| Quantitative engine | mch_stock_engine v2.0 |
| Research OS config | ros-1.21.0 |
| Analysis as-of | 2026-10-13 (prices 2026-10-12) |
| Narrative authorship | claude-opus-5 · Claude Code, supervised, drafted 2026-08-16 |
| Human review | Marinus 2026-08-16 |
| Evidence | 8/8 load-bearing inputs sourced; 13/14 mandated claims cited |
| QA | scanned post-emit by the document-QA layer; the publication label (Draft / Research / Decision-level) is stamped on the published page, not authored here |
Load-Bearing Assumptions
DCF: WACC 8.0%, terminal multiple 12×, FY+5 revenue $8B. Triangulation leans 41% on DCF, 29% on PWEV, 18% on the Monte Carlo median, 12% on peer-implied value.
Appendix & audit trail — source log, data provenance, disclosures
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-10-12 | Price, market cap, EV, forward P/E | Alpha Vantage 2026-10-12 |
| MCH engine — trailing 52 weeks of daily bars | derived | 2026-10-12 | 52-week range (intraday high and low over the trailing year of the stock's own daily bars) | trailing 52 weeks of own daily bars (intraday high/low, 2025-10-13 to 2026-10-09, 250 sessions) |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-10-12 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-10-12 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-10-12 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-10-12 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-10-12 | Segment revenue and multiple; model margin = gross margin − the calibrated opex ratio (not a reported margin) | company_context (authored, tagged) |
| MCH qualitative analysis | inference | 2026-10-12 | Moat, regulatory risk, scenario macro, catalysts | company_context enrichment (authored) |
| MCH investment thesis & falsification triggers | house estimate | 2026-10-12 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Data Sources
- Prices, fundamentals, options chain, earnings — Alpha Vantage.
- Company filings (10-K / 10-Q) — SEC filings via EDGAR.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personal financial advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- This report is produced by the MCH Analysis quantitative research engine — valuation, scenarios, Monte Carlo and the decision layer are generated systematically from the disclosed inputs and the archetype/industry driver sets, and reviewed rather than written name-by-name. Every figure reconciles to the appendix and every score exposes its inputs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.